title: Trial watch: dual-acting combination meets heart failure end point.
authors.forename: Sarah
authors.initials: S
authors.lastname: Crunkhorn
mesh_terms: D000613:Aminobutyrates / Q000008:administration & dosage* / Q000737:chemistry; D057911:Angiotensin Receptor Antagonists / Q000008:administration & dosage / Q000737:chemistry; D001713:Biphenyl Compounds; D017322:Clinical Trials, Phase II as Topic / Q000639:trends; D004338:Drug Combinations; D023381:Endpoint Determination / Q000639:trends; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D013777:Tetrazoles / Q000008:administration & dosage* / Q000737:chemistry; D000068756:Valsartan
chemical_list: D000613:Aminobutyrates; D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D004338:Drug Combinations; D013777:Tetrazoles; D000068756:Valsartan; C549068:sacubitril and valsartan sodium hydrate drug combination